Converge Bio is on a mission to transform how scientists discover and develop therapeutics using generative AI. Founded by a team of experts in machine learning, bioinformatics, and molecular biology, the company was created to address a critical gap in the life sciences: the need for scalable, explainable, and customizable AI solutions that accelerate innovation while preserving scientific ownership and control.

Converge Bio delivers complete AI-powered solutions that integrate proprietary modeling, data pipelines, and intuitive interfaces tailored to real-world scientific workflows. Our models are trained extensively on molecular sequences across biochemical languages—including DNA, RNA and protein —enabling deep biological understanding across modalities.

Our platform is deployed across the drug development value chain, with a focus on two core areas:

ConvergeAb™ supports antibody design with functionalities such as de novo design, affinity maturation, IP expansion,  humanization and more across different antibody types such as, IgG, VHH, and scFv . It also ranks candidates based on binding, developability, and structural fitness to prioritize top hits.

ConvergeGEO™ optimizes codons, UTRs, promoters, and RNA folding to enhance protein yield in host-specific systems, serving DNA synthesis and protein production teams.

Built for flexibility, scale, and security, Converge Bio empowers scientists and R&D organizations to move faster, reduce costs, and solve complex problems without giving up control over their data or IP.